ClinicalTrials.gg
RecruitingNCT05278429Updated Apr 16, 2024

Robotic-assisted Exercise Training in Heart Failure With Reduced Ejection Fraction

An interventional study of Myosuit robotic device in Heart Failure, Systolic, sponsored by German Heart Institute. Recruiting at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-16.

Sponsored by German Heart Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Heart Failure, Systolic with a site in Germany — 2 open to participants now, 3 under way, none of them phase 3. Heart Failure, Systolic · Germany.

Started
2021
with 1 other
No phase
3 of 11
2 open now
Registered
9th of 11
by date
Lead sponsor
2 of 11
German Heart Institute

Among the 11 studies in Heart Failure, Systolic with a site in Germany, this one is one of 2 that started in 2021, is one of 3 with no phase, and was the 9th registered.

Heart Failure, Systolic

230 studies on the registry are indexed under Heart Failure, Systolic; 50 are open to participants now.

Browse Heart Failure, Systolic studies →

Open to participants now

2 of the 11 studies in Heart Failure, Systolic with a site in Germany are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 28 Heart Failure, Systolic studies recruiting now, 18 (64%) set no upper age limit and 2 (7%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Heart Failure, Systolic with a site in Germany, or all of them as a file.
02

Study summary

This study will address the challenging task of remobilizing patients with advanced chronic lung or heart failure in a functional New York Heart Association class III-IV by using an externally physically-supported exosuit movement therapy. This soft, wearable robot (Myosuit) assists mobilization according to individual needs by activating neuromuscular feedback systems, promoting physical activity and preventing early physical exhaustion.

The feasibility, tolerance and safety of a Myosuit assisted training was shown in a feasibility trial. In the efficacy trial, patients will be randomized in a 2:1 ratio for an exosuit-supported or non-supported exercise training protocol, training 3 units per week for 8 weeks. Assessment of outcome will be performed by various functional, mobility and endurance tests, questionnaires and clinical parameters. Furthermore, the transfer of regained motor and balance skills to everyday life will be analyzed.

03

Conditions studied

  • Heart Failure, Systolic

Keywords

  • Exercise training
  • Robotic training
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >17 years old
  • written
  • chronic end-stage systolic heart failure without ventricular assist device, ≤ 45%
  • clinically stable for at least 6 weeks
  • ability to mobilize into standing and walking of at least 10 meters with or without rollator
  • ability to get up from a chair without rotating the upper body >45° sagittally

Exclusion criteria

Exclusion Criteria:

  • addictions or other illnesses that impact the ability to understand the nature, scope and
  • consequences of the trial
  • lack of knowledge of German to fully understand study information
  • pregnancy, pre-menopausal women
  • of cardiopulmonary exercising
  • > 35 kg/m², waist size > 135 cm.
  • Height \<150 cm, >195 cm
  • Weight\<45 kg, >110 kg
  • Functional Reach Test \<15,24 cm
  • Flexion contracture in the knee/hip joint >10°
  • Chronic colonization or active infection with multi-resistant pathogens
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Active comparator
    Myosuit arm

    Patients perform exercise training with the Myosuit

    Device: Myosuit robotic device

  • Other
    Control arm

    Patients perform exercise training without the Myosuit

    Device: Myosuit robotic device

Interventions

  • DeviceMyosuit robotic device

    The Myosuit is a partially soft, exoskeleton-type, wearable robot that supports the synergistic extension of the hip and knee joints.

06

What researchers measure

Primary outcomes

  1. Exercise capacity improves more in patients who trained with robotic support

    Exercise capacity is measured by six-minute walking test in meters

    Time frame: 8 weeks

  2. Exercise capacity improves more in patients who trained with robotic support

    Exercise capacity is measured by six-minute walking test in meters

    Time frame: 4 weeks

  3. Mobility improves more in patients who trained with robotic support

    Mobility is measured by timed-up-and-go tests in seconds

    Time frame: 8 weeks

  4. Mobility improves more in patients who trained with robotic support

    Mobility is measured by timed-up-and-go tests in seconds

    Time frame: 4 weeks

  5. Balance improves more in patients who trained with robotic support

    Balance is measured by berg balance tests via berg balance scale (0-56 points, the higher, the better).

    Time frame: 8 weeks

  6. Balance improves more in patients who trained with robotic support

    Balance is measured by berg balance tests via berg balance scale(0-56 points, the higher, the better).

    Time frame: 4 weeks

  7. Exercise training improves quality of life

    Quality of life is measured by Kansas City Cardiomyopathy Questionnaire

    Time frame: 8 weeks

  8. Heart failure Progression: Ejection fractions

    Change of echocardiographic findings: ejection fraction (in %)

    Time frame: 4 weeks

  9. Heart failure Progression: Diameters

    Change of echocardiographic findings: diameters (in mm)

    Time frame: 8 weeks

  10. Heart failure Progression: valve regurgitations

    Change of echocardiographic findings: regurgitations (grad I-V)

    Time frame: 8 weeks

  11. Heart failure Progression: elevated filling pressures

    Change of echocardiographic findings: end-diastolic pressure (elevated or normal)

    Time frame: 8 weeks

  12. Heart failure Progression: volume status

    Change of echocardiographic findings: vena cava diameter (in mm)

    Time frame: 8 weeks

  13. Change in Heart failure biomarkers: NT-proBNP

    Heart failure biomarkers: NT-proBNP

    Time frame: 8 weeks

  14. Change in Heart failure biomarkers: hsTroponin

    Heart failure biomarkers: hsTroponin

    Time frame: 8 weeks

  15. Change in inflammatory biomarkers: hsCRP

    Inflammatory biomarkers: NT-proBNP (in ng/mL)

    Time frame: 8 weeks

  16. Change in inflammatory biomarkers: IL-6

    Inflammatory biomarkers: IL-6

    Time frame: 8 weeks

Secondary outcomes

  1. Device acceptability

    measured by a acceptability questionnaire (9 questions, Score 9 to 63, the higher, the better).

    Time frame: 8 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2021 (actual). Primary completion is estimated for Jan 2025, 38 months after the start.

Of 52 non-industry interventional studies with no phase under Heart Failure, Systolic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 50. This study's planned 38 months is above that.

Counting every sponsor, half of 56 studies reached it within 30 months; a quarter within 16 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2021
First posted
Mar 14, 2022
StartActual
Nov 1, 2021
Primary completionEst.
Jan 2025
CompletionEst.
Jan 2025
Last update
Apr 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05278429
Lead sponsor
German Heart Institute
Collaborators
ETH Zurich, Charite University, Berlin, Germany
Responsible party
Sponsor
First posted
Mar 14, 2022
Start date
Nov 1, 2021
Primary completion
Jan 2025 (estimated)
Completion
Jan 2025 (estimated)
Last update
Apr 16, 2024

Study contacts

Isabell A Just, MD
Contact
herzsport@dhzb.de
00493045932025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion